Dr. John Cush RheumNow
1 year 8 months ago
Adalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or… https://t.co/J1CRgC3GJz https://t.co/8eOSvl5zZm
Dr. John Cush RheumNow
1 year 8 months ago
JAMA Case: 58-Year-Old Woman With Urticaria, Fever, and Joint Pain. 2 yrs daily fatigue, arthralgia (hands, feet, shoulders, knees), myalgia, intermittent fevers (>38.5°C). NL CBC, CRP 20.9 mg/L. negative dsDNA, ANCA, ENA, nl LFTs. What do you do next?… https://t.co/aY70tEhJ5Y https://t.co/QaK1G7RJkp
Dr. John Cush RheumNow
1 year 8 months ago
🚨 Join us for the 7th Annual RheumNow Live 2/8 - 2/9 : Where Innovation Meets Impact in Rheumatology! 🚨
🗓 2025| In-Person & Virtual
💻 Virtual: Stream + Q&A access (spots still open!)
Don’t miss the rheumatology event of the year!
👉 Register today:… https://t.co/Rf4U6JcdKs https://t.co/ilG2M7aRYS
Dr. John Cush RheumNow
1 year 8 months ago
Quick study of Henoch-Schönlein Purpura (HSP) in Children: An Overview https://t.co/LPFFDIeJPA https://t.co/PlTD0fOR2E
Dr. John Cush RheumNow
1 year 8 months ago
Getting to Remission - Without Biologics
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.… https://t.co/knadKyxIpb https://t.co/OVSauZeetx
Dr. John Cush RheumNow
1 year 8 months ago
Proinflammatory Diet Increases Gout Risk
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated.
https://t.co/DS6JDfJZI4 https://t.co/U3Xwq96oGj
Dr. John Cush RheumNow
1 year 8 months ago
Epidemiology of idiopathic inflammatory myopathies (IIMs) has incidence rates ranging from 0.2 to 2 cases per 100 000 person-years. https://t.co/tUWpijtKWX https://t.co/Mb66cZ1Aga
Dr. John Cush RheumNow
1 year 8 months ago
Korean Study of 10,013 #SLE pts (91%F)those on immunosuppressives were not at greater risk for cancer. Total CA risk (n 368) was 59 per 10,000 PYs. Most common Thyroid, breast, Gastric, colon & cervical. https://t.co/R0s7ZXaUoX https://t.co/jAc5mgtmlm
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. We also have two call-in cases on "Ask Cush Anything".Be sure to join in the fun at RNL 2025 next weekend - Gong Show Karaoke; what will you sing?
Dr. John Cush RheumNow
1 year 8 months ago
QD clinics - lessons from the Clinic brought to you by RheumNow Live 2025
https://t.co/REMEN3gIjo https://t.co/P676QhAKwT
Dr. John Cush RheumNow
1 year 8 months ago
ACR Applauds Second Round of Medicare Drug Price Negotiations
The ACR applauded the announcement of additional drugs subject to pricing negotiations with the CMS. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare… https://t.co/z1LkpWMXqg https://t.co/hqjkqTqJxw
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Dr. John Cush RheumNow
1 year 8 months ago
SubAnalysis of STOP Gout Trial: 277 pts w/ CKD received either allopurinol or febuxostat. Most achieved SUA goal (79% vs 81%), fewer allopurinol pts had gout flares (32% vs 45%; P=0.02); AKI only seen stage w/ 3 CKD (allopurinol > febuxostat) https://t.co/wwfVCei4Ej https://t.co/W8Y7KxcSd4
A large cohort of 18-year-old Swedish males were followed longitudinally for cardiovascular, respiratory, and musculoskeletal outcomes. They found that high body mass index (BMI) and smoking in youth were linked to the studied diseases later in life.
